Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Omer Pamuk

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Arthritis Care & Research|February 12, 2025
Temporal Trends and Demographic Insights Into Mortality From Systemic Lupus Erythematosus, 1999-2020Ansaam Daoud, Loai Dweik, Omer Pamuk
Drugs & Aging|April 19, 2021
Authors' Reply to Moura et al.: "Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk"Suraj Rajasimhan, Omer Pamuk, James D Katz
Rheumatic Diseases Clinics of North America|July 3, 2021
Lupus CohortsChristopher Redmond, Omer Pamuk, Sarfaraz A Hasni
Drugs & Aging|June 10, 2020
Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic RiskSuraj Rajasimhan, Omer Pamuk, James D Katz
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Arthritis Care & Research|February 12, 2025
Temporal Trends and Demographic Insights Into Mortality From Systemic Lupus Erythematosus, 1999-2020Ansaam Daoud, Loai Dweik, Omer Pamuk
Drugs & Aging|April 19, 2021
Authors' Reply to Moura et al.: "Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk"Suraj Rajasimhan, Omer Pamuk, James D Katz
Rheumatic Diseases Clinics of North America|July 3, 2021
Lupus CohortsChristopher Redmond, Omer Pamuk, Sarfaraz A Hasni
Drugs & Aging|June 10, 2020
Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic RiskSuraj Rajasimhan, Omer Pamuk, James D Katz
Pageof 1